This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Balance Sheet Health

Financial Health criteria checks 2/6

MorphoSys has a total shareholder equity of €-334.7M and total debt of €1.7B, which brings its debt-to-equity ratio to -518.3%. Its total assets and total liabilities are €1.7B and €2.0B respectively.

Key information

-518.3%

Debt to equity ratio

€1.73b

Debt

Interest coverage ratio	n/a
Cash	€512.31m
Equity	-€334.72m
Total liabilities	€2.04b
Total assets	€1.71b

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: MOR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MOR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: MOR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MOR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MOR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MOR has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 33.9% each year.

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/11/21 05:23
End of Day Share Price	2024/10/15 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MorphoSys AG is covered by 35 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Olav Zilian	Baader Helvea Equity Research
Brian Balchin	Barclays
Rosie Turner	Barclays